Purpose: To investigate the activity of carboplatin and cetuximab in NSCLC.
Patients And Methods: This was a single arm, multicenter phase II trial, and the primary objective was response rate.
Results: The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95% CI, 1.9-3.6), the median overall survival was 8.2 months (95% CI, 4.9-10.5), and 1-year survival rate was 33% (95% CI, 21-45).
Conclusion: The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/07357900903286958 | DOI Listing |
Publication Analysis
Top Keywords
carboplatin cetuximab
12
multicenter phase
8
phase trial
8
survival months
8
months 95%
8
trial carboplatin
4
cetuximab treatment
4
treatment advanced
4
advanced nonsmall
4
nonsmall cell
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!